[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mobility-disability\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mobility-disability":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,76,92,122,151,266],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100627312","phase-2-proof-of-concept-study-evaluating-total-body-weight-physical-function--safety-of-enobosarm-in-patients-treated-with-glp-1-receptor-agonist-for-weight-loss-100627312",false,"NCT07446998","Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss","PLATEAU: Phase 2b Proof-of-Concept Study to Evaluate the Effect on Total Body Weight, Physical Function and Safety of Enobosarm in Patients Treated With Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, for Weight Reduction","PLATEAU","Inclusion Criteria:\n\n* Subjects accepted for this study must:\n\n  1. Provide informed consent from the subject or the subject's legally authorized representative\n  2. Be able to communicate effectively with the study personnel\n  3. Be ≥65 years of age at the time of screening\n  4. For Female Subjects Menopausal status\n\nBe postmenopausal as defined by either:\n\n* one year or more of amenorrhea\n* surgical menopause with bilateral oophorectomy\n* Be premenopausal or perimenopausal with a negative pregnancy test.\n* If subject is of child bearing potential, the subject must agree to use acceptable methods of contraception: If female study participant could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 30 days following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository \\[i.e., barrier method of contraception\\], surgical sterilization of male partner (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository}, oral contraceptives (combination estrogen\u002Fprogesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository)\n\nIf female study participant has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) should also be used\n\nIf female study participant has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) should also be used For Male Subjects\n\nSubject must agree to use acceptable methods of contraception:\n\nIf the study subject's partner could become pregnant, use acceptable methods of contraception from the time of the first administration of study medication until 30 days following administration of the last dose of study medication. Acceptable methods of contraception are as follows: Condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository \\[i.e., barrier method of contraception\\], surgical sterilization (vasectomy with documentation of azoospermia) and a barrier method {condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository}, the female partner uses oral contraceptives (combination estrogen\u002Fprogesterone pills), injectable progesterone or subdermal implants and a barrier method (condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository)\n\nIf female partner of a study subject has undergone documented tubal ligation (female sterilization), a barrier method (condom used with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) should also be used\n\nIf female partner of a study subject has undergone documented placement of an intrauterine device (IUD) or intrauterine system (IUS), a barrier method (condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository) should also be used\n\nFemale partner is menopausal as defined above\n\n5\\. Medically indicated for use of semaglutide for weight reduction 6. Have BMI ≥35 7. Consents to continue treatment with semaglutide for up to 476 days under this protocol. 8. Subject is willing to comply with the requirements of the protocol through the end of the study 9. The patient is able to swallow oral medications 10.The patient is able to complete the physical function (stair climb) assessment 11.Maximum weight at screening of 350lbs as per DXA requirements\n\nExclusion Criteria\n\nAny of the following conditions are cause for exclusion from the study:\n\n1. Known hypersensitivity or allergy to enobosarm or a GLP-1 receptor agonist\n2. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m2 as measured using the chronic kidney disease-epidemiology collaboration (CKD-EPI) calculation (patients with mild and moderate renal failure are not excluded from participation in this study)\n3. Treatment with any investigational product within \\\u003C 5 half-lives for each individual investigational product OR within 30 days prior to randomization\n4. Major surgery (the surgery poses a significant risk to patients life and requires general anesthesia) within 30 days prior to randomization\n5. Planned major surgery during the course of the study or any cosmetic surgery potentially impacting body composition, e.g., liposuction, implants, or removal of any current implants\n6. Testosterone, methyltestosterone, oxandrolone (Oxandrin®), oxymetholone, danazol, fluoxymesterone (Halotestin®), testosterone-like agents (such as dehydroepiandrosterone, androstenedione, and other androgenic compounds, including herbals), myostatin inhibitors, apelin receptor agonists, or antiandrogens (flutamide, bicalutamide, abiraterone, enzalutamide, apalutamide, or darolutamide).\n\n   Previous therapy with testosterone and testosterone-like agents is acceptable with a 30-day washout (if previous testosterone therapy was long term depot within the past 6 months, the site should contact the Medical Monitor) or any other androgenic agent.\n7. An abnormal ECG result which, based on the investigator's clinical judgment, would place the subject at increased medical risk. A QTcF \\>450 ms for males and \\>460 ms for females is also exclusionary from this protocol.\n8. Concurrently participating in any other interventional or treatment clinical trial.\n9. Pre-existing liver disease (hepatitis B, uncontrolled hepatitis A, hepatitis C, autoimmune hepatitis, liver cancer, alcohol-associated cirrhosis, alcohol-associated hepatitis, alcohol-associated fatty liver)\n10. Baseline ALT or AST \\>3x upper limit of normal\n11. Baseline total bilirubin levels \\>upper limit of normal (except in cases of Gilbert's Syndrome)\n12. History of acute pancreatitis within one year of screening or history of chronic pancreatitis\n13. Severe gastrointestinal disease, including gastroparesis\n14. Major depressive disorder diagnosed within 2 years prior to screening (NOTE: a diagnosis of major depressive disorder ≥2 years prior to screening that is stably managed \\[with or without pharmacological intervention\\] without additional exclusionary history are not excluded from the study), history of other severe psychiatric disorder, including schizophrenia and bipolar disorder, any lifetime history of suicide attempt, or with suicidal ideation or behavior within 1 month prior to screening.\n15. Patient Health Questionnaire score \\>15 or any suicidal ideation of type 4 or type 5 on the Columbia-Suicide Severity Rating Scale\n16. Monogenic or syndrome obesity, and endocrine causes of obesity (such as untreated hypothyroidism or Cushing's syndrome), and obesity caused by medications that cause weight gain\n17. Prior bariatric surgery or weight loss devices unless removed for ≥1 year prior to screening for this study.\n18. Diagnosis of diabetes requiring current use of any antidiabetic drug or HbA1c ≥6.5%\n\n    Note: Metabolic syndrome is not an exclusion, even if managed with an anti-diabetic drug such as metformin or an SGLT2 inhibitor. A diagnosis of prediabetes or impaired glucose tolerance managed with antidiabetic medication or non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion as long as other study criteria are met and the patient has not progressed to a diagnosis of diabetes.\n19. Creatine kinase \\>1.5x ULN\n20. Any condition that is exclusionary for use of semaglutide (generally WEGOVY) in the patient. See the WEGOVY Prescribing Information. The following contraindications are listed in the WEGOVY prescribing information:\n\n    1. Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2\n    2. Known hypersensitivity to semaglutide or any of the excipients in WEGOVY.\n21. Subjects with active or untreated malignancy within 5 years of screening (NOTE:\n\n    treated non-melanoma skin cancers are allowable).\n22. Male subjects with a lifetime history of malignant prostate disease, such as prostate cancer.\n23. Male subjects with a PSA ≥4 ng\u002FmL\n24. Patients with prior tendon rupture or those taking concomitant medications that increase the risk of tendon rupture (e.g., fluroquinoline antibiotics, bempedoic acid, or chronic use of systemic corticosteroids).\n25. Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg). NOTE: blood pressure may be retested as per the investigator criteria as needed.\n26. Patients with a resting heart rate ≥100 beats per minute. NOTE: heart rate may be retested as per the investigator criteria as needed.\n27. Patients that have received a GLP-1 Receptor Agonist (e.g., semaglutide) or a GIP\u002FGLP-1 Receptor agonist (e.g., tirzepatide) within 12 months of Screening.\n28. Patients that wear foreign objects, at the discretion of the DXA technician, that cannot be removed at the time of DXA that could cause artifacts and decrease accuracy of exam, such as waist beads (e.g., for religious purposes).","ALL","65 Years","100 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The primary objective of this study is to assess the effect of enobosarm on total body weight",[28,29,30],"Obesity & Overweight","Mobility Disability","HOMA-IR","RECRUITING","2026-06-30",{"date":34,"type":35},"2026-07-01","ACTUAL",{"date":37,"type":35},"2026-03-26",{"date":39,"type":22},"2027-12",{"name":41,"class":42},"Veru Inc.","INDUSTRY",14,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100607956","reduction-of-depression-in-people-with-disabilities-through-dual-treatment-digital-cbt--nbhwc-coaching-100607956","NCT07195292","Reduction of Depression in People With Disabilities Through Dual Treatment: Digital CBT & NBHWC Coaching","Reduction of Depression Through Dual Mental Health Treatment: Digital-Based Cognitive Behavioral Therapy (CBT) and National Board for Health and Wellness Coaching (NBHWC) Mental Health Coaches for People With Disabilities (ReDu)","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Presence of self-reported hearing or mobility disability\n* Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study\n* Male or female, age 22 years or older\n* A score of 17 or higher on the HAM-D\n* Clinical diagnosis of depression based on DSM-5 diagnostic criteria\n* Willingness to adhere to the Toivoa-002 or sham regimen once per week, including scheduling and weekly meetings with coaches\n* Access to necessary resources for participating in a technology-based intervention (e.g., Android phone, iPhone, iPad, internet access)\n* Treatment stability (no changes in psychotropic medication or psychotherapy treatment in the 30 days prior to study entry)\n* Able to read and speak English fluently\n* Resident of the United States and living in the United States for the duration of the trial\n\nExclusion Criteria:\n\n* Medical diagnosis of psychotic disorder or bipolar disorder\n* Participation in another treatment trial at the time of study\n* Substance use disorder in the past 12 months (excluding tobacco)\n* Suicide attempt in the past year or elevated suicide risk other than passive ideation (i.e., endorsing items reflecting intent, identifying means, suicide planning, or suicide-related preparations).\n* Currently pregnant, breastfeeding, or planning to become pregnant during the treatment period","22 Years",{"count":21,"type":22},[54],"NA","The purpose of this study is to see if a mobile-delivered mental health program called Toivoa-002, which combines digital cognitive behavioral therapy (CBT) with personal mental health coaching, can effectively reduce depression in adults with hearing or mobility disabilities. The study aims to answer whether this dual-intervention digital service is more effective at lowering depression symptoms over an 8-week period than a \"sham\" digital program that is developed to look similar but does not contain active therapeutic content. The investigators hypothesize that participants who use the Toivoa-002 program will show significantly greater reductions in depression compared to those using the sham program, and that these mental health benefits will last through a 12-week follow-up. Adults within the disability community frequently encounter unique environmental and societal barriers - such as limited physical accessibility, transportation challenges, and workplace inflexibility - that can directly drive or worsen depression. By offering a fully remote and accessible mobile tool, this study seeks to determine if a digital health service can deliver scalable, effective depression relief tailored to the lived experiences of people with disabilities.",[57,58,29],"Hearing Disability","Depression",[58,60,61,62,63,64,65],"Anxiety","People with Hearing or Mobility Disability","Accessible Health for People with Disabilities and Veterans","Cognitive Behavioral Therapy","Cognitive Behavioral Therapy with Coaches","Coaches","NOT_YET_RECRUITING",{"date":68,"type":35},"2026-07-02",{"date":70,"type":22},"2026-08",{"date":72,"type":22},"2027-03",{"name":74,"class":42},"Toivoa Inc",4,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":91,"locationsCount":75},"100603744","reduction-of-anxiety-in-people-with-disabilities-through-dual-treatment-digital-cbt--nbhwc-coaching---a-randomized-clinical-trial-100603744","NCT07140497","Reduction of Anxiety in People With Disabilities Through Dual Treatment: Digital CBT & NBHWC Coaching - A Randomized Clinical Trial","Reduction of Anxiety Through Dual Mental Health Treatment: Digital-Based Cognitive Behavioral Therapy (CBT) and National Board for Health and Wellness Coaching (NBHWC) Mental Health Coaches for People With Disabilities (RADD)","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Presence of self-reported hearing or mobility disability\n* Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study\n* Males and females; Age 22 years and above\n* Score of 15 or higher on the HAM-A\n* Clinical diagnosis of anxiety based on DSM-5 diagnostic criteria\n* Willingness to adhere to the Toivoa-001 or sham regimen once per week, including scheduling and weekly meetings with coaches\n* Access to necessary resources for participating in a technology-based intervention (e.g., Android phone, iPhone, iPad, internet access)\n* Treatment stability (no changes in psychotropic medication or psychotherapy treatment in the 30 days prior to study entry)\n* Able to read and speak English fluently\n* Resident of the United States and living in the United States for the duration of the trial\n\nExclusion Criteria:\n\n* Medical diagnosis of psychotic disorder or bipolar disorder\n* Participation in another treatment trial at the time of study\n* Substance use disorder in the past 12 months (excluding tobacco)\n* Suicide attempt in the past year or elevated suicide risk other than passive ideation (i.e., endorsing items reflecting intent, identifying means, suicide planning, or suicide-related preparations)\n* Currently pregnant, breastfeeding, or planning to become pregnant during the treatment period",{"count":21,"type":22},[54],"The purpose of this study is to see if a mobile-delivered mental health program called Toivoa-001, which combines digital cognitive behavioral therapy (CBT) with personal mental health coaching, can effectively reduce anxiety in adults with hearing or mobility disabilities. The study aims to answer whether this dual-intervention digital service is more effective at lowering anxiety symptoms over an 8-week period than a \"sham\" digital program that is developed to look similar but does not contain active therapeutic content.\n\nThe investigators hypothesize that participants who use the Toivoa-001 program will show significantly greater reductions in anxiety compared to those using the sham program, and that these mental health benefits will last through a 12-week follow-up.\n\nAdults within the disability community frequently encounter unique environmental and societal barriers - such as limited physical accessibility, transportation challenges, and workplace inflexibility - that can directly drive or worsen anxiety. By offering a fully remote and accessible mobile tool, this study seeks to determine if a digital health service can deliver scalable, effective anxiety relief tailored to the lived experiences of people with disabilities.",[57,60,29],[60,58,61,62,63,64,65],{"date":68,"type":35},{"date":70,"type":22},{"date":72,"type":22},{"name":74,"class":42},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":104,"conditions":105,"keywords":106,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100605377","phase-1-cocoa-to-maximize-exercise-training-in-older-adults---the-comet-trial-100605377","NCT07161726","Cocoa to Maximize Exercise Training in Older Adults - The COMET Trial","COMET","Inclusion Criteria:\n\n* Age 55 years and older\n* Slow walking speed of \\\u003C 1m\u002Fs\n* Willingness to be randomized to either treatment group\n* Willingness to participate in all study procedures (muscle biopsy will be optional)\n\nExclusion Criteria:\n\n* Failure to provide informed consent;\n* Regular consumption of flavanol and\u002For cocoa supplements\n* Current involvement in supervised rehabilitation\u002Fexercise training program\n* Absolute contraindication(s) to exercise training according to American College of Sports Medicine guidelines \\[17\\]\n* Daytime average of systolic blood pressure ≥ 180\u002F100mm Hg.\n* Refusal to stop blood thinners such as baby aspirin dose.\n* Peripheral vascular disease; peripheral neuropathy; retinopathy\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina;\n* Myocardial infarction or stroke within past year\n* Significant cognitive impairment, including known dementia diagnosis or a Mini-Mental State Examination exam score \\\u003C 24\n* Progressive, degenerative neurologic disease, e.g., Parkinson's Disease, multiple sclerosis;\n* Severe rheumatologic or orthopedic diseases, e.g., awaiting joint replacement, active inflammatory disease;\n* Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen;\n* Hip fracture, hip or knee replacement, or spinal surgery within past 4 months;\n* Other significant co-morbid conditions that would impair ability to participate in the exercise-based intervention\n* Simultaneous participation in another interventional trial","55 Years",{"count":101,"type":22},36,[103,25],"PHASE1","The purpose of the study is to see if regular exercise when combined with a cocoa supplement will improve physical performance and muscle strength compared to regular exercise alone.",[29],[107,108,109,110],"Cocoa","Exercise","Mobility","Older adults","2026-05-07",{"date":113,"type":35},"2026-05-08",{"date":115,"type":35},"2026-04-21",{"date":117,"type":22},"2027-12-31",{"name":119,"class":120},"University of Alabama at Birmingham","OTHER",1,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":121},"100634466","impact-of-loss-aversion-messaging-and-anticipated-regret-for-inaction-on-exercise-adherence-in-older-adults-100634466","NCT07540052","Impact of Loss Aversion Messaging and Anticipated Regret for Inaction on Exercise Adherence in Older Adults","Testing the Impact of Loss Aversion Messaging and Anticipated Regret for Inaction on Exercise Adherence in Older Adults: A Randomized Pilot Trial","Inclusion Criteria:\n\n* Completed 12 months of FAST intervention\n\nExclusion Criteria:\n\n* No planned surgeries within the upcoming 4 months",{"count":130,"type":22},148,[54],"The goal of this clinical trial is to learn if messages focused on not losing the functional benefits of exercise can help older adults with walking difficulty continue to exercise regularly. The main questions it aims to answer are:\n\nDo these messages make people more likely to anticipate regretting it if they do not exercise? Does more anticipated regret make it more likely they will exercise more regularly?\n\nResearchers will compare two versions of messages to see if the content of these one of these message types is more effective than the other.\n\nParticipants will complete a daily 5-minute at home exercise program for 4 months and complete regular online surveys to track their progress and report their feelings regarding regret.",[29,134],"Walking Difficulty",[136,137,138,139,140,141],"exercise adherence","older adults","mobility disability","walking difficulty","pilot study","randomized controlled trial","2026-04-16",{"date":144,"type":35},"2026-04-20",{"date":146,"type":22},"2026-06",{"date":148,"type":22},"2027-07",{"name":150,"class":120},"Milton S. Hershey Medical Center",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":167,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":265},"100579228","home-based-brain-stimulation-for-motoric-cognitive-risk-syndrome-100579228","NCT06821568","Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome","Long-term Home-based Transcranial Electrical Stimulation for Cognitive and Motor Function in Older Adults With an Increased Risk of Dementia: a Randomized Controlled Trial","TDCS4MCR","Inclusion Criteria:\n\n* Men and women\n* Age 65-90 years\n* Subjective cognitive complaints as defined by a 'Yes' response to \"Do you feel that you have more problems with memory than most?\" or a 'No' response to \"is your mind as clear as it used to be?\"\n* Montreal Cognitive Assessment (MoCA) score ≥21\n* Slow gait speed as measured by averaging two 4-Meter walks and defined as a usual walking speed one standard deviation below age and sex-adjusted means.\n* Absence of significant disability as defined by the ability to walk over the instrumented gait mat unassisted (e.g., able to walk without any walking aids for at least 2 minutes non-stop) and preserved activities of daily living as defined by a score of less than 9 on the Functional Activities Questionnaire.\n* Identification of an eligible informant\n* Identification of a willing and able tDCS-administrator; i.e., a study partner to lead the administration of home-based transcranial direct current stimulation (tDCS)\n* Access to reliable WiFi in the participant's home\n\nExclusion Criteria:\n\n* Formal education less than the 8th grade\n* Previous physician diagnosis of dementia\n* Any current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depressive disorder)\n* Evidence of moderate-to-severe depressive symptoms defined by a score of ≥9 on the 15-item Geriatric Depression Scale\n* History of head trauma resulting in prolonged loss of consciousness\n* History of fainting spells of unknown or undetermined etiology that might constitute seizures\n* History of seizures, diagnosis of epilepsy, or immediate (first-degree relative) family history of epilepsy except for a single seizure of benign etiology (e.g. febrile seizures) in the judgment of a board-certified neurologist\n* Hospitalization within the past three months due to acute illness, or as the result of a musculoskeletal injury significantly affecting gait or balance\n* Any unstable medical condition or chronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) or study complication\n* Substance use disorders within the past six months\n* A hairstyle or headdress that prevents electrode contact with the scalp or would interfere with the stimulation (for example thick braids, hair weave, afro, wig)\n* Chronic vertigo\n* Myocardial infarction within the past 6 months\n* Active cancer for which chemo-\u002Fradiation therapy is being received\n* Legal blindness\n* Visual hallucinations (history or self-report)\n* Pacemaker\n* Contraindications to MRI or tDCS, including unprovoked seizure within the past two years, risk of ferromagnetic objects anywhere in the body, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.), the presence of any active dermatological condition, such as eczema, on the scalp, etc. as outlined by current recommendations for noninvasive brain stimulation endorsed by the International Federation for Clinical Neurophysiology.\n* History of REM sleep behavior disorder (RBD), often an early sign of Parkinson's disease\n* Medications and medical history will be reviewed by the responsible covering physician and a decision about inclusion will be made based on the participant's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS active drugs.","90 Years",{"count":161,"type":22},128,[54],"The objective of this study is to determine the effects of a 6-month, home-based personalized transcranial direct current stimulation (tDCS) intervention targeting the left dorsolateral prefrontal cortex on cognitive function, dual task standing and walking, and other metrics of mobility in older adults with motoric cognitive risk syndrome (MCR).",[165,166,29],"Alzheimer Disease and Related Dementias","Cognition",[168,60,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244,245,246,247,248,249,250,251,252,253,254,255],"Anatomy","Atrophic","Behavioral","Brain","Brain Region","Cephalic","Cognitive","Communities","Dementia","Development","Dose","Double-Blind Method","Electric Stimulation","Enrollment","Evaluation","Exhibits","Exposure to","Frequencies","Future","Gait","Gait Speed","Genetic Crossing Over","Home","Impaired Cognition","Individual","Intervention","Intervention Studies","Magnetic Resonance Imaging","Measurable","Measures","Mood","Motor","Multi-Institutional Clinical Trial","Neuronal Plasticity","Outcome","Participant","Performance","Phase","Pilot Projects","Prefrontal Cortex","Randomized","Randomized Controlled Clinical Trials","Research","Resolution","Rest","Risk","Series","Site","Structure","Testing","Therapeutic","Time","Syndrome","Walking","Work","Arm","cerebral atrophy","Clinically relevant","cognitive task","Cost","Dementia Risk","Design","Executive Function","functional improvement","functional near infrared spectroscopy","Gray Matter","high risk","home test","improved","insight","late life","mental function","neural network","neuroimaging","noninvasive brain stimulation","normal aging","older adult","older men","older women","open label","primary endpoint","response","secondary outcome","smartphone application","transcranial direct current stimulation","trial design","walking speed","Alzheimer's Disease","2025-09-17",{"date":258,"type":35},"2025-09-22",{"date":260,"type":35},"2025-09-02",{"date":262,"type":22},"2029-06",{"name":264,"class":120},"Hebrew SeniorLife",2,{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":274,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":265},"100588333","the-impact-of-biological-mechanisms-of-aging-on-response-variability-to-resistance-training-in-older-adults-100588333","NCT06940037","The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults","The Impact of Biological Mechanisms of Aging on Response Variability to Resistance Training in Older Adults (BRIO): A Randomized, Placebo-controlled Trial of Progressive Resistance Training in Older Adults.","BRIO","Inclusion Criteria:\n\n* aged greater than or equal to 65 years\n* sedentary (Community Healthy Activities Model Program for Seniors physical activity questionnaire to identify and exclude persons engaged in regular (125 min\u002Fweek or more) moderate intensity physical activity\n* at risk for mobility disability score of less than or equal to 10 (but greater than 3) on the SPPB\n* willing to be randomized into HE or PRT\n* willing to be transported or transport themselves to the clinical sites for the intervention and assessments\n\nExclusion Criteria:\n\n* unwillingness to provide informed consent\n* participation in lifestyle or pharmacologic intervention trial or structured program of exercise training in the past 6 months\n* an SPPB score of less than or equal to 3\n* osteoarthritis or condition with joint pain limiting daily life activities\n* significant weight loss or gain (7.5% of body weight) in past six months\n* current anti-coagulant or anti-platelet therapy (Coumadin, Eliquis, Pradaxa, Xarelto, heparin, Lovenox, Plavix)\n* clinically significant abnormality in any of the screening laboratory values, including those identified as outside of the \"normal limits', that are deemed to be of concern for participation in the study by the study physician\n* acute or terminal illness\n* Mini Mental State Exam (MMSE) \\\u003C23\n* myocardial infarction in the previous 6 months or other symptomatic coronary artery disease\n* New York Heart Association Class III or IV congestive heart failure\n* serious conduction disorder (e.g., 3rd degree heart block), uncontrolled arrhythmia, or new Q waves or ST-segment depressions (\\>3 mm) on ECG\n* chronic obstructive pulmonary disease requiring oxygen therapy\n* upper or lower extremity fracture in the previous 6 months\n* uncontrolled hypertension (150\u002F90 mm Hg)\n* neuromuscular diseases and\u002For drugs which affect neuromuscular function\n* current use of anabolic steroids, growth hormone, replacement androgen therapy, anti-androgen therapy\n* allergy to lidocaine\n* presence of significant liver or renal disease (eGFR \\\u003C 45 mL\u002Fmin)\n* diagnosis of type I diabetes mellitus or insulin requiring type 2 diabetes mellitus\n* HbA1c \\> 7%\n* BMI \\\u003C21 or \\>35 for men or \\>40 for women\n* excessive alcohol intake (\\>14 alcoholic beverages per wk.)\n* current tobacco use\n* current participation in any interventional clinical trial\n* current use of weight loss medications",true,{"count":276,"type":22},300,[54],"To critically examine biological, clinical, and behavioral modulators of progressive resistance training-associated exercise response heterogeneity in physical function and whole-body metabolism in older adults.",[280,29],"Aging",[282,283,284,285,286,287],"aging","mobility","exercise","senescence","DNA methylation","skeletal muscle","2025-09-15",{"date":290,"type":35},"2025-09-16",{"date":292,"type":35},"2025-08-11",{"date":294,"type":22},"2030-08-31",{"name":296,"class":120},"Mayo Clinic"]